Combination ACE inhibitors and angiotensin II receptor blockers for hypertension.
OBJECTIVE
To review data concerning combined angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) therapy for hypertension.


METHODS
MEDLINE (1966-April 2003), IPA (1970-April 2003), and EMBASE (1974-April 2003) with search terms of ACE inhibitor, angiotensin receptor blocker, essential hypertension, and combination therapy.


RESULTS
ACE inhibitors provide incomplete blockade of the renin-angiotensin system, sometimes leading to loss of blood pressure control. Addition of ARBs may in theory further reduce blood pressure. Studies of combined ACE inhibitor and ARB therapy for managing hypertension were evaluated.


CONCLUSIONS
While studies have shown statistically significant blood pressure reductions with ACE/ARB combination therapy, clinical significance is lacking. Further trials are needed before routine use of the combination can be recommended.
Finnegan
Patrick M
PM
St. Louis College of Pharmacy, St. Louis, MO 63110-1088, USA.
Gleason
Brenda L
BL
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors